URCC NCORP Research Base

URCC NCORP研究基地

基本信息

批准号：
10673773
负责人：
KAREN M. MUSTIAN
金额：
$ 600.88万
依托单位：
UNIVERSITY OF ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-08-01 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10673773
关键词：
Achievement Age American Society of Clinical Oncology Award Behavioral Biological Biological Markers Cancer Center Cancer Control Cancer Control Research Cancer Patient Cancer Survivor Cancer health equity Caregivers Caring Clinic Clinical Clinical Cancer Center Clinical Oncology Clinical Research Clinical Research Associate Clinical Trials Cluster randomized trial Collection Committee Members Communities Community Clinical Oncology Program Community Networks Conduct Clinical Trials Data Development Enrollment Epigenetic Process Ethics Ethnic Origin Etiology Funding Gender Goals Grant Immunologics Immunotherapy Individual Innovative Therapy Intervention Journals Knowledge Leadership Malignant Neoplasms Manuscripts Medical Oncologist Mentors Minority Minority Groups Modernization Morbidity - disease rate NCI Center for Cancer Research National Cancer Institute Nature Nurses Oncologist Oncology Operative Surgical Procedures Outcome Pathway interactions Patient Care Patients Peer Review Persons Phase Physicians Physiological Pilot Projects Positioning Attribute Prevalence Procedures Productivity Program Development Prospective, cohort study Protocols documentation Publications Publishing Quality of Care Race Radiation Oncologist Radiation therapy Randomized Reduce health disparities Reporting Research Research Personnel Resources Risk Scientific Inquiry Severities Sex Orientation Site Supportive care Surgeon Survivors Symptoms System Testing Toxic effect Training Treatment Side Effects Treatment-related toxicity Underserved Population United States Universities Vision Woman Work anticancer research base cancer care care delivery chemotherapy clinical care data acquisition design experience gene therapy health disparity health equity hormone therapy human subject protection improved innovation intervention delivery investigator training member novel participant enrollment programs psychosocial randomized, clinical trials recruit side effect stem symptom science system-level barriers treatment guidelines virtual

项目摘要

ABSTRACT: The University of Rochester Cancer Center (URCC) National Cancer Institute Community Oncology Research Program (NCORP) Research Base (RB) is a RB with 35+ years of experience conducting cancer control research (CCR) and cancer care delivery research (CCDR). The URCC NCORP RB’s vision is "to help good people through lousy times when they experience cancer” by reducing cancer- and treatment- related morbidity stemming from toxicities and side effects. Since 2014, 35% (N=2,831) of all NCORP accrual credits resulted from enrollment of patients and survivors by our Community Affiliates on our 13 active URCC clinical trials. URCC and its Community Affiliates also enrolled 421 caregivers and more than 300 oncologists to our 13 active trials, as well as 1,752 patients and survivors to our 29 local pilot studies. URCC successfully enrolled and randomized over 30 individual community oncology practices to cluster randomized trials. Our investigators and staff submitted 8 new concepts/grants, with 18 new concepts/grants currently in development, and 29 active pilot studies. The significant and innovative contribution of URCC research to scientific knowledge and clinical care is evidenced by 1) 197 published manuscripts, 2) 209 presented abstracts, 3) 25 podium presentations at ASCO, 4) 82 outstanding research awards to our investigators, 5) 12 junior investigators successfully trained to conduct research in NCORP, and 6) 2,215 investigators, clinicians, and staff successfully trained to implement URCC NCORP RB protocols at community sites across the United States. Notable recognition of the significance of research conducted by the URCC RB and its investigators includes: 1) Best of JCO publication for 2017, 2) most cited article in JAMA Oncology for 2017, 3) one of the most significant advances in cancer research and care for 2018, 4) citation of our published research in virtually all existing supportive care treatment guidelines, and 5) leadership by 5 of our RB Executive Committee members in the development of 4 supportive care treatment guidelines. We accomplish our goal of reducing cancer- and treatment-related morbidity by working with cancer patients, survivors, and their caregivers from 592 community oncology practices across the United States to design and conduct CCR and CCDR, including translational and health equity outcomes, focused in symptom science. Our research develops and tests novel treatments for toxicities and side effects stemming from cancer and its treatments. We design and conduct phase I-III randomized clinical trials and longitudinal, prospective cohort studies. To meet its responsibilities as a RB and maintain its high level of productivity over the next funding period, the URCC RB will focus its resources and expertise on the following specific aims: Aim 1) to conduct CCR, Aim 2) to conduct CCDR, Aim 3) to conduct translational CCR, Aim 4) to conduct health equity CCR and CCDR, and Aim 5) to provide state-of-the-art training and mentoring for NCORP investigators and staff. With its proven track record of productivity and innovation, the URCC NCORP RB is expertly positioned to continue its pioneering symptom science research in the NCORP Network.

摘要：罗切斯特大学癌症中心 (URCC) 国家癌症研究所社区肿瘤学研究计划 (NCORP) 研究基地 (RB) 是一个拥有 35 年以上开展研究经验的 RB 癌症控制研究 (CCR) 和癌症护理提供研究 (CCDR) URCC NCORP RB 的愿景是通过减少癌症和治疗，“帮助好人度过癌症的痛苦时期” 自 2014 年以来，占所有 NCORP 应计费用的 35% (N=2,831)。学分来自于我们的社区附属机构将患者和幸存者纳入我们的 13 个活跃 URCC URCC 及其社区附属机构还招募了 421 名护理人员和 300 多名肿瘤学家来参与临床试验。我们的 13 项正在进行的试验以及 1,752 名患者和幸存者参加了我们的 29 项本地试点研究。我们招募并随机化了 30 多个社区肿瘤学实践进行聚类随机试验。研究人员和工作人员提交了 8 个新概念/赠款，其中 18 个新概念/赠款目前正在开发中，以及 29 项活跃的试点研究 URCC 研究对科学知识的重大和创新贡献。临床护理由 1) 197 篇发表的手稿、2) 209 篇提交的摘要、3) 25 篇讲台证明在 ASCO 上的演讲，4) 我们的研究人员获得 82 项杰出研究奖，5) 12 名初级研究人员成功地接受了在 NCORP 进行研究的培训，并且 6) 2,215 名调查员、牧师和工作人员成功地受过培训以在美国各地的社区站点实施 URCC NCORP RB 协议。对 URCC RB 及其研究人员进行的研究重要性的认可包括： 1) Best of 2017 年 JCO 出版物，2) 2017 年《JAMA 肿瘤学》中被引用次数最多的文章，3) 最重要的进展之一 2018 年癌症研究和护理领域，4) 在几乎所有现有支持性护理中引用我们已发表的研究治疗指南，以及 5) 由 5 名 RB 执行委员会成员领导制定 4 我们实现了减少癌症和治疗相关的目标。通过与来自 592 个社区肿瘤诊所的癌症患者、幸存者及其护理人员合作，了解发病率在美国各地设计和实施 CCR 和 CCDR，包括转化和健康公平我们的研究重点是症状科学，开发并测试新的毒性和治疗方法。我们设计并进行 I-III 期随机临床。履行其作为 RB 的职责并保持其高水平。为了提高下一个资助期间的生产力，URCC RB 将把其资源和专业知识集中在以下方面具体目标：目标 1) 进行 CCR，目标 2) 进行 CCDR，目标 3) 进行转化 CCR，目标 4) 开展健康公平 CCR 和 CCDR，目标 5) 为以下人员提供最先进的培训和指导 NCORP 的调查人员和工作人员凭借其在生产力和创新方面的良好记录，URCC NCORP RB 拥有专业优势，可以在 NCORP 网络中继续其开创性的症状科学研究。